Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
{{output}}
The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted agents interfering with... ...
